US panel to discuss paediatric data requirements for Revatio in PAH
This article was originally published in Scrip
Executive Summary
A US FDA advisory panel will meet on 29 July to discuss what data are needed to support extending use of Pfizer's pulmonary arterial hypertension treatment Revatio (sildenafil) to children – and also to review in general what studies to request for other products intended to treat paediatric PAH.